These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 33043761)
41. Sex differences in vascular reactivity in mesenteric arteries from a mouse model of acute intermittent porphyria. Pulgar VM; Yasuda M; Gan L; Desnick RJ; Bonkovsky HL Mol Genet Metab; 2019 Nov; 128(3):376-381. PubMed ID: 30639047 [TBL] [Abstract][Full Text] [Related]
42. Givosiran for Acute Intermittent Porphyria. Reply. Balwani M; Sardh E; Gouya L N Engl J Med; 2020 Nov; 383(20):1989-1990. PubMed ID: 33176092 [No Abstract] [Full Text] [Related]
43. Open-label study of hemin for acute porphyria: clinical practice implications. Anderson KE; Collins S Am J Med; 2006 Sep; 119(9):801.e19-24. PubMed ID: 16945618 [TBL] [Abstract][Full Text] [Related]
44. Givosiran for Acute Intermittent Porphyria. Gomá-Garcés E; Pérez-Gómez MV; Ortíz A N Engl J Med; 2020 Nov; 383(20):1989. PubMed ID: 33176091 [No Abstract] [Full Text] [Related]
45. Idiosyncratic drug-induced liver injury caused by givosiran in a patient with acute intermittent porphyria. Ma CD; Faust D; Bonkovsky HL Mol Genet Metab Rep; 2023 Mar; 34():100946. PubMed ID: 36578356 [TBL] [Abstract][Full Text] [Related]
47. Hereditary Coproporphyria Mimicking Guillain-Barré Syndrome After COVID-19 Infection. Upchurch M; Donnelly JP; Deremiah E; Barthol C; Hafeez S; Anderson KE; Seifi A Cureus; 2022 Jan; 14(1):e21586. PubMed ID: 35228944 [TBL] [Abstract][Full Text] [Related]
48. Renal Function Decline With Small Interfering RNA Silencing Aminolevulinic Acid Synthase 1 (ALAS1). Lazareth H; Poli A; Bignon Y; Mirmiran A; Rabant M; Cohen R; Schmitt C; Puy H; Karras A; Gouya L; Pallet N Kidney Int Rep; 2021 Jul; 6(7):1904-1911. PubMed ID: 34307985 [TBL] [Abstract][Full Text] [Related]
49. Cimetidine in the treatment of acute intermittent porphyria. Rogers PD Ann Pharmacother; 1997 Mar; 31(3):365-7. PubMed ID: 9066947 [TBL] [Abstract][Full Text] [Related]
50. Health impact of acute intermittent porphyria in latent and non-recurrent attacks patients. Buendía-Martínez J; Barreda-Sánchez M; Rodríguez-Peña L; Ballesta-Martínez MJ; López-González V; Sánchez-Soler MJ; Serrano-Antón AT; Pérez-Tomás ME; Gil-Ferrer R; Avilés-Plaza F; Glover-López G; Carazo-Díaz C; Guillén-Navarro E Orphanet J Rare Dis; 2021 Feb; 16(1):106. PubMed ID: 33639982 [TBL] [Abstract][Full Text] [Related]
51. Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved Li J; Liu J; Zhang X; Clausen V; Tran C; Arciprete M; Wang Q; Rocca C; Guan LH; Zhang G; Najarian D; Xu Y; Smith P; Wu JT; Chong S Drug Metab Dispos; 2021 Jul; 49(7):572-580. PubMed ID: 33941543 [TBL] [Abstract][Full Text] [Related]
52. High disease burden and healthcare resource usage in patients with acute porphyria-A population-based analysis. Stölzel U; Ambrosius B; Brun S; Tacke F Liver Int; 2024 Oct; 44(10):2639-2650. PubMed ID: 39016183 [TBL] [Abstract][Full Text] [Related]
53. EXPLORE B: A prospective, long-term natural history study of patients with acute hepatic porphyria with chronic symptoms. Cassiman D; Kauppinen R; Monroy S; Lee MJ; Bonkovsky HL; Thapar M; Guillén-Navarro E; Minder AE; Hale C; Sweetser MT; Ivanova A J Inherit Metab Dis; 2022 Nov; 45(6):1163-1174. PubMed ID: 36069414 [TBL] [Abstract][Full Text] [Related]
54. Recurrent symptoms of acute intermittent porphyria after biochemical normalization with givosiran-An ongoing clinical conundrum. Ma CD; Faust D; Bonkovsky HL JIMD Rep; 2023 Mar; 64(2):146-149. PubMed ID: 36873084 [TBL] [Abstract][Full Text] [Related]
55. High penetrance of acute intermittent porphyria in a Spanish founder mutation population and CYP2D6 genotype as a susceptibility factor. Barreda-Sánchez M; Buendía-Martínez J; Glover-López G; Carazo-Díaz C; Ballesta-Martínez MJ; López-González V; Sánchez-Soler MJ; Rodriguez-Peña L; Serrano-Antón AT; Gil-Ferrer R; Martínez-Romero MDC; Carbonell-Meseguer P; Guillén-Navarro E Orphanet J Rare Dis; 2019 Feb; 14(1):59. PubMed ID: 30808393 [TBL] [Abstract][Full Text] [Related]
56. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. D'Avola D; López-Franco E; Sangro B; Pañeda A; Grossios N; Gil-Farina I; Benito A; Twisk J; Paz M; Ruiz J; Schmidt M; Petry H; Harper P; de Salamanca RE; Fontanellas A; Prieto J; González-Aseguinolaza G J Hepatol; 2016 Oct; 65(4):776-783. PubMed ID: 27212246 [TBL] [Abstract][Full Text] [Related]
57. Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden. Andersson C; Innala E; Bäckström T J Intern Med; 2003 Aug; 254(2):176-83. PubMed ID: 12859699 [TBL] [Abstract][Full Text] [Related]
58. Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. Jeans JB; Savik K; Gross CR; Weimer MK; Bossenmaier IC; Pierach CA; Bloomer JR Am J Med Genet; 1996 Nov; 65(4):269-73. PubMed ID: 8923933 [TBL] [Abstract][Full Text] [Related]
59. Premenstrual attacks of acute intermittent porphyria: hormonal and metabolic aspects - a case report. De Block CE; Leeuw IH; Gaal LF Eur J Endocrinol; 1999 Jul; 141(1):50-4. PubMed ID: 10407223 [TBL] [Abstract][Full Text] [Related]